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Abstract
Objectives The aim of this study was to compare the expres-
sion of host-derived markers in peri-implant/gingival crevic-
ular fluid (PCF/GCF) and clinical conditions at ceramic im-
plants and contralateral natural teeth. As a secondary objec-
tive, we compared zirconia implants with titanium implants.
Methods One zirconia implant (ZERAMEX® Implant
System) and one contralateral natural tooth were examined
in 36 systemically healthy subjects (21 males, 15 females,
mean age 58). The levels of Il-1β, Il-1RA, Il-6, Il-8, Il-17,
b-FGF, G-CSF, GM-CSF, IFN , MIP-1β, TNF-α, and
VEGF were assessed in PCF/GCF using the Bio-Plex 200
Suspension Array System. The plaque index (PI), gingival
index (GI), probing depth (PD), and bleeding on probing
(BOP) were assessed at six sites around each implant or tooth.
Titanium implants were also assessed when present (n = 9).
Results The zirconia implants were examined after a loading
period of at least 1.2 years (average 2.2 years). The mean PI
was significantly lower at zirconia implants compared to teeth
(p = 0.003), while the mean GI, PD, and BOP were signifi-
cantly higher (p < 0.001). A correlation was found in the
expression of Il-1RA, Il-8, G-CSF, MIP-1β, and TNF-α at
zirconia implants and teeth. The levels of IL-1β and TNF-α
were significantly higher at zirconia implants than at teeth. No
significant differences were found between zirconia and tita-
nium implants. A correlation was found between the levels of
IL-1RA, IL-8, GM-CSF, and MIP-1β at zirconia and titanium
implants.
Conclusions The correlation in the expression of five bio-
markers at zirconia implants and teeth, and of four biomarkers
at zirconia and titanium implants, is compatible with the exis-
tence of a patient-specific inflammatory response pattern.
Higher mean GI, PD, and BOP around implants suggests that
the peri-implant mucosa may be mechanically more fragile
than the gingiva.
Clinical relevance Similar expression of selected biomarkers
at zirconia implants and teeth and at zirconia and titanium
implants reflects existence of patient-specific inflammatory
response patterns.
Keywords Zirconia . Dental implants . Cytokines
Introduction
The prevalence of peri-implantitis at titanium implants is es-
timated in the order of 10% implants and 20% patients during
5 to 10 years after implant placement [1]. Some authors have
suggested adverse immune reactions to titanium oxide as a
possible contributing factor to biological complications [2,
3]. To what extent peri-implant infections could be lowered
by choosing another implant material is unknown. Zirconia
ceramics have been proposed as an alternative. Favorable
physical and chemical properties [4], color adaptability,
claims of high biocompatibility [5], and low affinity to plaque
[6] have made zirconium dioxide (ZrO2) a material of partic-
ular interest. So far, the available evidence for specific benefits
of dental zirconia implants is however incomplete. The num-
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Analysis of gingival crevice fluid (GCF) has been sug-
gested as a way of evaluating host response in the periodontal
tissues [8]. It offers a simple, non-invasive way of studying
cellular and metabolic events taking place in the periodontal
environment [9, 10]. In analogy, analysis of peri-implant crev-
ice fluid (PCF) was proposed [11]. Among mediators identi-
fied in the GCF and PCF, cytokines have attracted particular
interest. Secreted by a broad range of cells, these soluble pro-
teins have a crucial role in innate and adaptive immunity and
are thus important factors in the host response to infection (for
review, see 12). Using the experimental gingivitis model, GCF
levels of the cytokine IL-1 were demonstrated to increase
rapidly with plaque accumulation and in advance of the sub-
sequent gingival inflammation, indicating that some cytokines
may be early markers of gingival inflammatory changes [12].
Recent studies suggest that elevated levels of pro-
inflammatory cytokines in PCF may be markers for early
peri-implant infections at titanium implants and may have
value in indicating patients at risk for such pathology
[13–16]. Pro-inflammatory cytokines have been assessed at
titanium implants with zirconia or titanium abutments [17]
but thus far have not been studied in PCF at zirconia implants.
Since November 2009, we have treated a series of partially
edentulous patients with a total of 76 two-piece zirconia im-
plants supporting all-ceramic crowns. Treatment outcomes in-
cluding 2-year cumulative survival rates were presented re-
cently [18]. In a limited number of these patients, titanium
implants were also present. This gave us the opportunity to
assess the clinical and biological conditions at zirconia im-
plants and teeth and, in a subset of participants, to compare
them with titanium implants. The specific objective of this
investigation was to measure and compare the expression of
host-derived markers in PCF at zirconia implants and GCF of
contralateral natural teeth.
Material and methods
This was a cross-sectional investigation of 36 participants tak-
ing part in a single-center, open-labeled, longitudinal case se-
ries. The Ethical Committee of the University Hospitals of
Geneva, Geneva, Switzerland, approved the protocol.
Research was conducted according to the principles outlined
in the Declaration of Helsinki on human medical experimen-
tation. Each participant signed a written informed consent.
Patients
The patients included in this study were partially edentulous
adults with at least one zirconia implant carrying a full-
ceramic crown. They had been recruited between November
2009 and June 2012 among systemically healthy individuals,
aged 20 or over, seeking treatment for replacement of missing
teeth at the University of Geneva School of Dental Medicine,
Geneva, Switzerland. Persons with an increased risk for com-
plications, i.e., those with current major systemic or oral pa-
thologies, or subjects needing extensive preparatory treat-
ments of hard or soft tissues in order to make implant place-
ment possible, had not been included. The following condi-
tions were explicit exclusion criteria: smoking more than ten
cigarettes per day, addicted to alcohol or other substances,
heavily overweight, severely compromised general health,
and extensive bone loss in the area of prospective
implantation.
All participants had been treated with a two-piece implant
system (ZERAMEX®, Dentalpoint AG, Zürich, Switzerland),
consisting of an implant body and an abutment, bothmade from
highly dense zirconium dioxide (ZrO2-ATZ-Bio-HIP, Metoxit
AG, Thayngen, Switzerland). Thirteen patients were treated
with the ZERAMEX 1st generation presenting with a sand-
blasted surface, 23 with the ZERAMEX T implant presenting
with a sand-blasted and acid-etched surface. The abutments
were bonded into the implants with an adhesive resin-cement
(Panavia™ F, Kuraray, Tokyo, Japan). Full-ceramic crowns
were made from lithium disilicate glass-ceramic (IPS e.max
Press, Ivoclar Vivadent AG, Schaan, Lichtenstein). In 9 of the
36 individuals available for the present analysis, previously
placed titanium implants could also be examined. They were
all from the same manufacturer (Straumann® Dental Implant
System; Institut Straumann AG, Basel, Switzerland), had a
sand-blasted and acid-etched surface (SLA), and had been
placed at various time points before 2009. The study popula-
tion, the treatment protocol, and results from longitudinal mon-
itoring up to 588 ± 174 days after loading have been previously
presented [18].
Clinical protocol
One zirconia implant and one contralateral natural tooth were
examined after at least 1 year of function of the implant. If
available, one previously placed titanium implant was also
examined. If multiple zirconia or titanium implants were pres-
ent, the most mesially located implant of each type was select-
ed. One investigator (D.H.) performed all clinical procedures.
She recorded the dental and medical history, including antibi-
otics taken within 3 months of the examination date, and took
standardized photographs and peri-apical radiographs. The
clinical examination included an assessment of the plaque
index (PI) and gingival index (GI) [19], probing depth (PD)
and bleeding on probing (BOP) at six sites around each im-
plant and natural tooth.
Samples of PCF and GCF were taken from the mid-buccal
and mid-lingual/palatal crevice area at the selected implants
and teeth as previously described [9]: Study sites were isolated
from saliva with cotton rolls. Any supra-gingival plaque was
carefully removed with cotton pellets. Each site was
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individually dried with an aspiration tip. The newly formed
crevice fluid was collected after 2 min with a 2 × 6-mm strip of
Durapore® membrane, pore size 0.22 μm (Millipore,
Bedford, MA, USA). The strip was gently placed at the en-
trance of the crevice (Fig. 1), left in situ for 1 min, and then
transferred into a microtube. The samples from the mid-buccal
and mid-lingual/palatal crevice area of the same unit were
pooled. Samples visibly contaminated by blood were
discarded. The specimens were stored at −20 °C until
analyzed.
Laboratory procedures
Biomarkers were assessed in PCF and GCF using a multiplex
fluorescent bead-based immunoassay and the Bio-Plex 200
suspension array system (Bio-Rad Laboratories, Hercules,
CA, USA). The human cytokine 12-plex kit (Kit
M5000HIVRK, Bio-Rad Laboratories, Hercules, CA, USA)
included the following 12 cytokines: Il-1β, Il-1RA, Il-6, Il-8,
Il-17, basic FGF, G-CSF, GM-CSF, IFN-γ, MIP-1β VEGF,
and TNF-α. The assays were performed in 96-well filter plates
according to the instructions of the manufacturer. In brief, the
specimens were eluted in the assay buffer provided in the
system’s kit. Microsphere beads coated with monoclonal an-
tibodies against the 12 analytes were added. P/GCF samples,
controls, and standards were incubated for 30 min in separate
wells. Using vacuum filter, the wells were washed, and a mix-
ture of biotinylated secondary antibodies was added. After
another 30 min of incubation, the plates were washed again,
and streptavidin conjugated to the fluorescent protein phyco-
erythrin was added. After 10min, the plates were washed once
more to remove the unbound reagents, and the assay buffer
was added. The beads (minimum of 100/analyte) were ana-
lyzed in the suspension array system. The lowest detection
limit varied between 1 and 2.24 pg/ml, except for IL-1RA
and TNF-α, where the limits were 5.63 and 6.63 pg/ml,
respectively.
Data analysis
For all measurements recorded at six sites of implants and
teeth (PI, GI, PD, and BOP), an average (mPI, mGI, mPD,
mBOP) was calculated for the zirconia implant and the tooth
of each patient, if available also for the titanium implant. The
emergence profiles of the crowns were assessed on radio-
graphs (Fig. 2) as score 0 (gradual transition from the implant
to the crown) or score 1 (absence of a gradual transition, or
presence of an adjacent over- or under-contoured restoration,
or adjacent implants with connected supra-structures).
The biochemical read-outs were analyzed using Bio-Plex
Manager 3.0 (Bio-Rad Laboratories, Hercules, CA, USA). A
constant (0.1) was added to remove zero values. Because not
all data were normally distributed, differences between zirco-
nia implants and teeth, and differences between zirconia and
titanium implants, were analyzed using Wilcoxon matched-
pair signed-rank test, a non-parametric test. A Spearman’s
correlation was used to test the relationship between measure-
ments at implants and teeth. The Wilcoxon-Mann-Whitney
test was used to analyze differences between independent
groups. p values <0.05 were accepted for statistical
significance.
Table 1 Demographic data of the study participants
Number Percent
Participants 36 100
Gender, M/F 21/15 58/42
Mean age in years (SD) 54.3 (12.5) –
Smokers 5 14
Zirconia implants 36 100
Titanium implants 9 25
Maxillary implants 18 50
Mandibular implants 18 50
ZERAMEX 1st generation 13 36
ZERAMEX T 23 64
Fig. 2 Peri-apical radiograph of a zirconia implant-supported single
crown
Fig. 1 Peri-implant crevice fluid sampling using a Durapore®membrane
strip
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Results
Study population
Table 1 shows the demographic data for all participants. One
zirconia implant with an all-ceramic crown and one contralat-
eral natural tooth were examined in 36 subjects, 21(58 %)
male and 15(42 %) female, with a mean age of 54.3 ± 12.5
(range 26 to 76) years. In nine (25 %) participants, titanium
implants were also available for evaluation. All reconstruc-
tions, except one, were single-unit crowns (one subject had
two adjacent zirconia implants with connected supra-struc-
tures). Zirconia implants were examined after an average load-
ing period of 2.2 ± 0.75 years. Five subjects (14 %) were
smokers, and four (11 %) were treated with systemic antibi-
otics for reasons unrelated to the study within 3 months of the
examination date.
Comparison of zirconia implants and natural teeth
Table 2 shows the clinical results at zirconia implants and
teeth. The mPI was generally low and significantly correlated
between implants and teeth, nonetheless significantly lower
around zirconia implant-supported crowns than around teeth.
In fact, the mPI was 0 at the implants of 18 participants; at the
contralateral teeth, this was the case in eight participants. On
the contrary, mPD, mBOP, and mGI were all significantly
higher at the implants. Thirty-three (92 %) zirconia implants
compared to 30 (83%) natural teeth had at least one site with a
GI value of 2. Sites with GI = 3 were rarely seen (two partic-
ipants exhibited local signs of inflammation at a zirconia im-
plant with GI = 3. One different person scored GI = 3 at a
contralateral natural tooth).
Table 3 shows the mean level of 12 biochemical markers
measured at zirconia implants and teeth. IL-1RA showed the
highest mean values around both zirconia and teeth, followed
by VEGF, IL-8, G-CSF, IL-1β, and IFN . Generally, low
levels of IL-6, IL-17, b-FGF, GM-CSF, MIP-1β, and TNF-α
were detected around both zirconia implants and teeth. The
levels of IL-1β and TNF-α were significantly higher at im-
plants than at teeth. In contrast, a correlation was found in the
expression of five biomarkers at zirconia implants and teeth.
Figure 3 shows the individual levels of IL-8 at zirconia im-
plants and teeth (p = 0.001), the marker with the highest de-
gree of correlation (r = 0.567). Zirconia implants with crowns
with an emergence profile score of 0 (gradual transition from
the implant to the crown) had significantly higher levels of IL-
1RA (p = 0.032) and significantly lower levels of IL-6
(p = 0.041) than implants with an imperfect emergence pro-
file. An additional subgroup analysis suggested ZERAMEX
1st generation implants had higher levels of IL-1β, IL-8, and
TNF-α than ZERAMEX T implants.
Comparison of zirconia and titanium implants
Table 4 shows the clinical results at zirconia implants and
titanium implants. Table 5 shows the mean level of 12 bio-
chemical markers measured in nine individuals at zirconia and
Table 3 PCF/GCF biomarkers
levels as pg/ml per 1-min sample
at zirconia implants and teeth:
means (standard deviation), p of
difference, and Spearman’s rank
correlations (r, p for correlation),
n = 36 participants
Zirconia implants Teeth p difference r p correlation
IL-1β 415.7 (517.7) 222.1 (182.6) 0.016 0.317 n.s.
IL-1RA 63,066.1 (48,773.7) 62,251.3 (40,178.9) n.s. 0.361 0.039
IL-6 3.3 (2.3) 4.00 (4.2) n.s. 0.082 n.s.
IL-8 564.3 (361.8) 536.6 (341.8) n.s. 0.567 0.001
IL-17 30.1 (13.9) 27.4 (11.2) n.s. 0.247 n.s.
b-FGF 37.2 (14.3) 34.3 (9.9) n.s. 0.249 n.s.
G-CSF 438.3 (672.2) 348.5 (448.7) n.s. 0.536 0.001
GM-CSF 30.2 (7.6) 29.5 (5.8) n.s. 0.294 n.s.
IFN 113.5 (40.1) 101.6 (34.1) n.s. 0.210 n.s.
MIP-1β 23.0 (18.7) 23.9 (20.0) n.s. 0.444 0.010
TNF-α 18.9 (12.9) 15.3 (10.1) 0.048 0.497 0.003
VEGF 917.2 (708.5) 755.2 (501.1) n.s. 0.117 n.s.
Table 2 Clinical parameters at
zirconia implants and teeth:
means (standard deviation), p of
difference, and Spearman’s rank
correlations (r, p for correlation),
n = 36 participants
Zirconia implants Teeth p difference r p correlation
mPI 0.25 (0.49) 0.47 (0.60) 0.003 0.393 0.018
mGI 1.63 (0.48) 1.24 (0.50) <0.001 0.284 n.s.
mPD 3.41 (0.51) 2.81 (0.55) <0.001 0.346 0.039
mBOP 0.70 (0.29) 0.43 (0.30) <0.001 0.193 n.s.
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titanium implants. The mPI was significantly higher at titani-
um than at zirconia implants. There were no other significant
differences. Il-1RA, Il-8, G-CSF, and MIP-1β at zirconia and
titanium implants were significantly correlated.
Discussion
This is the first report comparing clinical and biological find-
ings around two-piece zirconia implant-supported crowns and
natural teeth. We found significant differences of several clin-
ical parameters and two biomarkers, and we noted significant
correlations between two clinical and five biological parame-
ters. PI scores at zirconia implants were generally low and
correlated to those at contralateral teeth, indicating that the
participants had a good overall level of oral hygiene.
Nevertheless, PI scores at zirconia implant-supported crowns
were significantly lower than at natural teeth and titanium
implants, corroborating reports of low affinity of zirconia to
plaque [6]. Perhaps surprisingly, mPD, mBOP, and mGI all
were, however, significantly higher at zirconia implants than
at teeth. It has previously been indicated that the verti-
cal position of the implant affects the dimensions of the
peri-implant tissues and that the distance from the im-
plant shoulder to the mucosal margin may be up to
5 mm in the anterior maxilla after the insertion of an
implant crown [20]. In another study, titanium implants
showed a lower mean plaque score and a higher median
pocket depth than teeth [16]. BOP at implants in the
order of 80 % has been noticed in numerous studies
[21–25]. This higher rate than around healthy teeth sug-
gests that the peri-implant mucosa may be mechanically
more fragile than gingiva. It is however unknown
whether bleeding upon peri-implant probing indicates
an increased risk for peri-implantitis. The disproportion
between the high frequency of BOP and clinically man-
ifest peri-implantitis indicates that there may be a high
false-positive rate (for review, see 1). The higher mGI
values around implants can be explained by the same
phenomenon—a GI score of 2 is given if bleeding oc-
curs after running a blunt instrument along the soft tis-
sue wall of the entrance of the gingival crevice [19].
The GI was originally defined to assess natural teeth,
not implants; hence, the modified sulcus bleeding index
[26] would have been more suitable for assessing im-
plants. However, since implants were compared to nat-
ural teeth in this study, utilization of GI for implants
was considered more appropriate.
The study’s split-mouth design permitted an intra-
individual comparison of cytokine levels in GCF and PCF
around the teeth and implants, respectively. The correlation
in the expression of five biomarkers at zirconia implants
and teeth, and of four biomarkers at zirconia and titanium
implants, is compatible with the existence of a patient-
specific inflammatory response pattern. The levels of two
biomarkers (IL-1β and TNF-α) were significantly higher at
zirconia implants than at teeth. Our results agree with find-
ings of a recent study comparing levels of biomarkers in
PCF at titanium implants and GCF, showing higher levels
of TNF-α at implants and significant positive correlations
between levels in PCF and GCF of several cytokines [16].
An overall higher concentration of cytokines was found
around titanium implants than at natural teeth in a second
study [27]. A third study [13], assessing host-derived bio-
markers in PCF at titanium implants and GCF at adjacent
teeth, showed no differences but indicated that PCF and
GCF levels of most analytes were correlated. In the review
process of this paper, a subgroup analysis with regards to
implant type was recommended. This analysis suggested
ZERAMEX 1st generation implants had higher levels of
three cytokines than ZERAMEX T implants. These results
could be better explained by the difference in the prosthetic
design rather than the difference in surface treatment be-
tween implants. However, findings of such secondary
Table 4 Clinical parameters at zirconia implants and titanium implants:
means (±standard deviation), p of difference, and Spearman’s rank
correlations (r, p for correlation), n = 9 participants
Zirconia Titanium p difference r p correlation
mPI 0.20 (0.29) 0.81 (0.86) 0.046 0.207 n.s.
mGI 1.59 (0.57) 1.59 (0.73) n.s. 0.181 n.s.
mPD 3.33 (0.48) 2.91 (0.82) n.s. −0.082 n.s.
mBOP 0.70 (0.32) 0.63 (0.34) n.s. 0.368 n.s.
Fig. 3 Individual levels of IL-8 (pg/ml per 1-min sample) at zirconia
implants and teeth. Each dot represents one participant. Spearman’s rank
correlation, r = 0.567, p = 0.001
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subgroup analyses need to be interpreted with caution [28].
A specifically designed study with larger size would be
required to determine to what extent differences in implant
design and surface treatment or implant dimensions and
implant position influence the expression of inflammatory
markers at zirconia implants.
In the present study, except for PI, no significant differ-
ences in clinical or biological parameters at titanium or zirco-
nium implants were found. Inflammatory profiles have been
evaluated at peri-implant soft tissues adjacent to either titani-
um or zirconia healing abutments after 6 months of healing
[5]. These authors noted a significant increase in pro-
inflammatory infiltrates and higher expressions of VEGF
and nitric oxide synthase isoforms 1 and 3 at titanium abut-
ments. In another experiment [17], pro-inflammatory cytokine
and bone metabolism mediator expression were not different
around titanium and zirconia implant abutments, with one
exception (leptin).
The biomarker levels obtained in this study were a result of
a pooled 1-minute sample from the vestibular and lingual/
palatal aspects of each tooth or implant. Differences in sam-
pling protocols hinder direct comparisons of average values
among studies. In addition, the cytokine threshold levels in
healthy conditions are not defined. However, MMP-8 and IL-
1beta levels were analyzed around teeth and implants during
the course of experimental peri-implant mucositis and gingi-
vitis [29]. Nonetheless, it has been acknowledged that an in-
crease in cytokine concentration is correlated with clinical
signs of peri-implantitis and periodontitis [27, 30, 31]. The
outcome of therapy with titanium implants was retrospective-
ly associated to results of assessments of several genetic and
immunological markers in 109 subjects [2]. Increasing num-
bers of risk genotypes of the studied polymorphisms were
associated with an increasing risk of implant loss, suggesting
an additive effect. IL-1 and TNF-α genotyping and cytokine
release assay scores represented risk factors for implant loss.
Conclusions
Although clinical parameters assessed at peri-implant
tissues of zirconia implants and periodontal tissues of
contralateral natural teeth showed significant differences,
by and large, a similar expression of pro-inflammatory
cytokines was observed. Correlations in the expression
of several biomarkers at zirconia implants and teeth, and
at zirconia and titanium implants, may reflect patient-
specific inflammatory response patterns that are not
modified locally by the implant material. The diagnostic
value of such markers to determine differential benefits
of zirconia or titanium implants remains to be deter-
mined in longitudinal studies.
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Table 5 PCF/GCF biomarkers
levels as pg/ml per 1-min sample
at zirconia implants and titanium
implants: means (standard
deviation), p of difference, and
Spearman’s rank correlations (r, p
for correlation), n = 9 participants
Zirconia Titanium p difference r p correlation
IL-1β 610.7 (901.5) 345.7 (241.3) n.s. 0.405 n.s.
IL-1RA 61,829.7 (56,396.1) 73,135.6 (60,864.4) n.s. 0.765 0.027
IL-6 2.8 (1.7) 5.1 (8.2) n.s. −0.048 n.s.
IL-8 691.9 (526.7) 573.5 (302.8) n.s. 0.881 0.004
IL-17 34.5 (15.0) 30.9 (±12.4) n.s. 0.143 n.s.
b-FGF 42.0 (18.5) 40.6 (11.1) n.s. 0.143 n.s.
G-CSF 378.5 (604.9) 643.6 (1177.6) n.s. 0.738 0.037
GM-CSF 29.9 (10.7) 32.0 (2.8) n.s. 0.690 n.s.
IFN 133.5 (52.7) 115.5 (22.2) n.s. 0.515 n.s.
MIP-1β 17.6 (9.7) 19.3 (11.4) n.s. 0.952 <0.001
TNF-α 21.1 (18.4) 17.1 (9.5) n.s. 0.214 n.s.
VEGF 953.5 (480.2) 923.5 (486.5) n.s. 0.119 n.s.
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